The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
|
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A286 - A286
  • [2] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [3] Cardio-renal protection with empagliflozin
    MacIsaac, Richard J.
    Jerums, George
    Ekinci, Elif I.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (20)
  • [4] COST EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH T2DM AND HIGH CV RISK IN CANADA
    Mettam, S. R.
    Bajaj, H.
    Kansal, A. R.
    Kandaswamy, P.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [5] Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension
    Tikkanen, I.
    Narko, K.
    Zeller, C.
    Green, A.
    Salsali, A.
    Broedl, U. C.
    Woerle, H. J.
    DIABETOLOGIA, 2013, 56 : S377 - S377
  • [6] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    DIABETOLOGIA, 2016, 59 : S26 - S26
  • [7] Predicting renal function decline in patients with T2DM
    George Jerums
    Richard J. MacIsaac
    Nature Reviews Endocrinology, 2014, 10 : 381 - 382
  • [8] Predicting renal function decline in patients with T2DM
    Jerums, George
    MacIsaac, Richard J.
    NATURE REVIEWS ENDOCRINOLOGY, 2014, 10 (07) : 381 - 382
  • [9] Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results
    Xue Tong
    Qun Yu
    Ghada Ankawi
    Bo Pang
    Bo Yang
    Hongtao Yang
    Diabetes Therapy, 2020, 11 : 1983 - 1999
  • [10] Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results
    Tong, Xue
    Yu, Qun
    Ankawi, Ghada
    Pang, Bo
    Yang, Bo
    Yang, Hongtao
    DIABETES THERAPY, 2020, 11 (09) : 1983 - 1999
12345